A randomized, double-blind, crossover study comparing the pharmacodynamic response in subjects with acute coronary syndrome receiving 14 days 10-mg MD prasugrel vs 14 days 150-mg MD [maintenance dose] clopidogrel after using a 900-mg LD [loading dose] of clopidogrel to reduce ongoing platelet activation.

Trial Profile

A randomized, double-blind, crossover study comparing the pharmacodynamic response in subjects with acute coronary syndrome receiving 14 days 10-mg MD prasugrel vs 14 days 150-mg MD [maintenance dose] clopidogrel after using a 900-mg LD [loading dose] of clopidogrel to reduce ongoing platelet activation.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Clopidogrel; Prasugrel
  • Indications Acute coronary syndromes; Embolism and thrombosis
  • Focus Pharmacodynamics
  • Acronyms ACAPULCO
  • Sponsors Eli Lilly
  • Most Recent Events

    • 01 Jan 2010 Results published in Thrombosis and Haemostasis.
    • 03 Nov 2009 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov.
    • 03 Nov 2009 Actual patient number (56) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top